Treatment of Primary Biliary Cirrhosis: Therapy with Choleretic and Immunosuppressive Agents

被引：22
作者：
Silveira, Marina G. [1 ]
Lindor, Keith D. [1 ]
机构：
[1] Mayo Clin, Div Gastroenterol & Hepatol, Miles & Shirley Fiterman Ctr Digest Dis, Rochester, MN 55905 USA
来源：
CLINICS IN LIVER DISEASE | 2008年 / 12卷 / 02期
关键词：
D O I：
10.1016/j.cld.2008.02.008
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease of presumed autoimmune etiology affecting predominantly middle-aged women; it is a slowly progressive disease causing loss of intrahepatic bile ducts, resulting hi advanced fibrosis, cirrhosis, and liver failure. Many drugs have been studied for treatment, including agents with choleretic and immunosuppressive properties. Ursodeoxycholic acid (UDCA) has been evaluated most widely. After fiver failure, the only effective treatment is liver transplantation. Effective therapy reduces the need for transplantation and improves life expectancy. For advanced liver disease or incomplete response to UDCA, new therapies to cure or retard the progression of disease in PBC are needed.
引用
收藏
页码：425 / +
页数：21
相关论文
共 112 条
[1]   Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis [J].
Angulo, P ;
Batts, KP ;
Therneau, TM ;
Jorgensen, RA ;
Dickson, ER ;
Lindor, KD .
HEPATOLOGY, 1999, 29 (03) :644-647
[2]   Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial [J].
Angulo, P ;
Dickson, ER ;
Therneau, TM ;
Jorgensen, RA ;
Smith, C ;
DeSotel, CK ;
Lange, SM ;
Anderson, ML ;
Mahoney, DW ;
Lindor, KD .
JOURNAL OF HEPATOLOGY, 1999, 30 (05) :830-835
[3]   Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid [J].
Angulo, P ;
Jorgensen, RA ;
Keach, JC ;
Dickson, ER ;
Smith, C ;
Lindor, KD .
HEPATOLOGY, 2000, 31 (02) :318-323
[4]  
Angulo P, 2001, AM J GASTROENTEROL, V96, P3152
[5]   Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid [J].
Angulo, P ;
Lindor, KD ;
Therneau, TM ;
Jorgensen, RA ;
Malinchoc, M ;
Kamath, PS ;
Dickson, ER .
LIVER, 1999, 19 (02) :115-121
[6]   Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy [J].
Babatin, M. A. ;
Sanai, F. M. ;
Swain, M. G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (05) :813-820
[7]  
Bach N, 2003, AM J GASTROENTEROL, V98, P187
[8]   URSODEOXYCHOLIC ACID IN THE TREATMENT OF CHOLESTEROL CHOLELITHIASIS .2. [J].
BACHRACH, WH ;
HOFMANN, AF .
DIGESTIVE DISEASES AND SCIENCES, 1982, 27 (09) :833-856
[9]  
BACHS L, 1989, LANCET, V1, P574
[10]   EFFECTS OF LONG-TERM RIFAMPICIN ADMINISTRATION IN PRIMARY BILIARY-CIRRHOSIS [J].
BACHS, L ;
PARES, A ;
ELENA, M ;
PIERA, C ;
RODES, J .
GASTROENTEROLOGY, 1992, 102 (06) :2077-2080
12345678910